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Research has consistently shown that genetics plays a critical role in prostate cancer 
(CaP) development, but the identification of CaP genes has proven to be very difficult.  
Hereditary prostate cancer is a complex disease believed to involve numerous genes 
and variable penetrance. It has been proposed that studying alternative, highly 
homogenous phenotypes related to CaP may be a solution for overcoming the 
apparent heterogeneity that has hindered the identification of susceptibility genes.  
Several recent studies have applied this idea to “aggressive” or “clinically significant”
cases of CaP.  Using the resources of the Utah Population Database, we identified two 
phenotypes often associated with non-aggressive disease that show significant 
familiality.  We present those results here.
Data Resource
• Utah Population Database (UPDB) 
• Records for approximately 2.2 million individuals
• Up to 9 generations of genealogical data linking individuals into pedigrees
• Linked to death certificates providing cause of death data since 1904
• Utah Cancer Registry (UCR)
• Part of Surveillance, Epidemiology and End Results (SEER) program since 1973
• All cancer events (except basal and squamous cell carcinomas) are recorded
• Fully linked to UPDB 
• 18,894 CaP cases from UCR currently linked to UPDB genealogies
Familial Relative Risk (FRR)
The resources of the UPDB make it possible to make population-based estimates of 
relative risk for family members of individuals with specific phenotypes.  Considering 
each CaP subgroup to be a unique condition, the table below shows the relative risk to 
first, second and third degree relatives of cases for developing the same phenotype.
•All examined subgroups have a significant familial risk component.
•Non-metastatic disease shows a greater a risk to extended family than general CaP.
•Cases diagnosed before age 65 and cases surviving more than 10 years have a risk 
significantly greater than general CaP for all three relative groups.
Linkage Analysis
Dominant and recessive parametric linkage analyses were performed for the CaP
subgroups with survival of greater than 10 years and with localized tumors.  All 
analyses were performed using the MCLINK software package at the Center for High 
Performance Computing at the University of Utah. Genotyping was performed by the 
Center for Inherited Disease Research (CIDR) on a full-genome set of 401 STR 
markers with an average spacing of 9 cM.  A summary of the pedigrees used and 
HLOD tracings are shown below.
Summary data for the 
orignial CaP linkage 








* connecting ancestors of cases, and spouse with up to four children were genotyped when necessary to infer genotypes
Table 2: Summary of pedigree characteristics for linkage analyses
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Figure 1: HLOD statistic for linkage to non-metastatic CaP.  The solid line represents the dominant model, and the broken 
line represents the recessive model.
Figure 2: HLOD statistic for linkage to CaP with survival of over 10 years.  The solid line represents the dominant model, 
and the broken line represents the recessive model.
Discussion
•No significant linkage evidence was observed at the genome-wide level for either of 
the phenotypes examined.
•Best result for the non-metastatic subgroup was HLOD = 1.50 in the dominant 
analysis at 58 cM on chromosome 9.
•Best result for the long survival subgroup was HLOD = 2.33 in the dominant model at 
40 cM on chromosome X.
•Signal is at Xp21-22, and is not associated with the HPCX locus at Xq27-28.
•Long survival appears to be correlated with early age at diagnosis, which is generally 
considered to be a trait of hereditary CaP cases.
•The pedigrees and genotypes used in this study were originally ascertained for a 
linkage analysis of general prostate cancer.  Considering only subgroups of the original 
cases results in fewer cases per pedigree and greater genetic distance between cases, 
increasing the possibility of confounding due to intra-familial heterogeneity.
•Further research is necessary to identify the genes responsible for hereditary prostate 
cancer and surmount the overarching problem of CaP heterogeneity.
